Mochida Pharmaceutical Co., Ltd. · TSE:4534
Mochida Pharmaceutical — FY2024 Q2 Earnings Presentation
27 slides from Mochida Pharmaceutical's earnings presentation, Nov 7, 2024
Slide 1: FY2024 Q2 Financial Results Presentation
FY2024 Q2 Financial Results Presentation (From April 1, 2024 to September 30, 2024) November 7, 2024 Mochida Pharmaceutical Co., Ltd.
Slide 2: Disclaimer (1/2)
Disclaimer (1/2) This material is an English translation of the Financial Results Presentation for the Fiscal Year 2024 Q2 to be issued on November 7, 2024 in Japanese, and the Japanese presentation is given priority regarding content and interpretation. The information provided in this material
Slide 3: Disclaimer (2/2)
Disclaimer (2/2) Approved products contain risks relating to manufacturing and marketing which include, but not are limited to, situations in which the Company may face deficiencies in manufacturing capacity needed to meet demand, difficulties in securing the supplies of raw materials, and demand
Slide 4: Agenda
Agenda • FY2024 Q2 Overview • FY2024 Forecast • Topics FY2024 Q2 Financial Results Presentation 4
Slide 5: FY2024 Q2 Overview
FY2024 Q2 Overview FY2024 Q2 Financial Results Presentation 5
Slide 6: Business environment
Business environment The NHI drug price list revision in April 2024. Decrease in drug prices (The drug price revision rate for all listed products was in the -9% range.) Increase in import prices of active pharmaceutical ingredients and pharmaceutical formulations due to depreciation of the ye
Slide 7: Summary of FY2024 Q2 (1/2)
Summary of FY2024 Q2 (1/2) Consolidated Financial Results Increase in Net sales Decrease in Operating profits Net sales increased due to the Operating profits decreased due to the NHI growth of new drugs drug price revision and the increase in the cost of sales ratio, which is caused by higher imp
Slide 8: Summary of FY2024 Q2 (2/2)
Summary of FY2024 Q2 (2/2) Progress in development pipeline Ethical drugs • Obtained manufacturing and marketing approval of Quviviq®, insomnia treatment • Obtained approval for an additional indication of Treprost® Inhalation Solution for pulmonary hypertension associated with interstitial lung d
Slide 9: Consolidated operating results in FY2024 Q2
Consolidated operating results in FY2024 Q2 （Millions of yen） FY2023 Q2 FY2024 Q2 Y o Y value (Y o Y changes) (Y o Y changes) 49,476 51,096 Net sales 1,619 (▲7.0％) (3.3％) 3,952 3,793 Operating profit ▲159 (▲25.1％) (▲4.0％) Ratio of operating 8.0％ 7.4% ▲0.6 points profit to net sales 4,053 4,079 Ordin
Slide 10: Net sales by business in FY2024 Q2
Net sales by business in FY2024 Q2 (Millions of yen) FY2023 Q2 FY2024 Q2 Y o Y value (Y o Y changes) (Y o Y changes) 49,476 51,096 Net sales 1,619 (▲7.0％) (3.3％) Pharmaceuticals 46,286 47,555 business 1,269 (▲7.8％) (2.7％) Healthcare 3,190 3,540 business 349 (6.4％) (11.0％) FY2024 Q2 Financial Results
Slide 11: Sales of major products in FY2024 Q2 (1/2)
Sales of major products in FY2024 Q2 (1/2) （Billions of yen） FY2024 Q2 Products FY2023 Q2 YoY Sales Value Ratio ■ New drugs Treatment of ulcerative colitis Lialda® 71 74 3 4% Treatment for chronic Goofice® 37 41 3 8% constipation Treatment for chronic Movicol® 28 32 3 11% constipation Gout and hyper
Slide 12: Sales of major products in FY2024 Q2 (2/2)
Sales of major products in FY2024 Q2 (2/2) （Billions of yen） FY2024 Q2 Products FY2023 Q2 YoY Sales Value Ratio ■ Long-listed products Drug for hyperlipidemia and arteriosclerosis obliterans Epadel 38 29 ▲9 ▲25% Antidepressant Lexapro® 26 17 ▲9 ▲34% Calcium channel blocker with a ＊ long-acting hypot
Slide 13: Consolidated financial statements
Consolidated financial statements （Millions of yen） Major fluctuation factors （Millions of yen） FY2023 FY2024 Q2 YoY （As of Mar. 31, 2024） （As of Sep. 30, 2024） value Y o Y value Total assets 158,800 158,434 ▲365 Cash and time deposits 7,401 Total current Accounts receivable ▲5,072 assets 116,662 11
Slide 14: Shareholder returns
Shareholder returns Maintaining a stable dividends while enhancing internal reserves for future business development Policy Maintaining the dividend of at least 80 yen per share during the 22-24 MTP period （Yen） FY2023 FY2024（Forecast） Annual dividends per 80.00 80.00 share （interim 40.00） （inte
Slide 15: FY2024 Forecast
FY2024 Forecast FY2024 Q2 Financial Results Presentation 15
Slide 16: Prospects and Challenges for FY2024
Prospects and Challenges for FY2024 Pharmaceuticals • Focusing on targeted areas with a focus on new drugs Expanding Lialda®, Omvoh® and Cortiment® by focus on the gastroenterology Further growth of Goofice® and Urece® etc. Dinagest and Dienogest • Changing business scheme of Quviviq® and te
Slide 17: Consolidated financial result forecasts
Consolidated financial result forecasts （Millions of yen） FY2023 FY2024 Forecast （Y o Y changes） （Y o Y changes） 102,885 106,000 Net sales (▲0.4％) (3.0％) 5,802 7,500 Operating profit (▲31.8％) (29.3％) Ratio of operating 5.6％ 7.1％ profit to net sales 6,037 7,700 Ordinary profit (▲33.5％) (27.5％) Profit
Slide 18: Forecasts by business
Forecasts by business （Millions of yen） FY2023 FY2024 (Y o Y changes) (Y o Y changes) 102,885 106,000 Net sales (▲0.4％) (3.0％) Pharmaceuticals 96,455 99,180 business (▲0.9％) (2.8％) Healthcare 6,430 7,000 business (8.6％) (8.9％) FY2024 Q2 Financial Results Presentation 18
Slide 19: Forecasts of major products (1/2)
Forecasts of major products (1/2) （Billions of yen） FY2024 Forecasts Products FY2023 YoY Sales Value Ratio ■ New drugs Treatment of ulcerative colitis Lialda® 145 146 1 1％ Treatment for chronic Goofice® 77 90 12 16％ constipation Treatment for chronic Movicol® 59 60 0 1％ constipation Gout and hyperur
Slide 20: Forecasts of major products (2/2)
Forecasts of major products (2/2) （Billions of yen） FY2024 Forecasts Products FY2023 YoY Sales Value Ratio ■ Long-listed products Drug for hyperlipidemia and arteriosclerosis obliterans Epadel 74 65 ▲8 ▲12％ Antidepressant Lexapro® 52 37 ▲15 ▲29％ Calcium channel blocker with a ®＊ long-acting hypotens
Slide 21: Development Pipeline: Ethical drugs
Development Pipeline: Ethical drugs Stage Remarks Development code Indications Phase Ⅱ Phase Ⅲ Filed Approved ＜Development country＞ Co-development with Nxera ＊1 Pharma Japan Co., Ltd. ACT-541468 Insomnia (Former Idorsia Pharmaceuticals Japan Ltd.) <Japan> Pulmonary hypertension Licensed-in from Unit
Slide 22: Development Pipeline: Medical devices
Development Pipeline: Medical devices Stage Intended use Remarks Development code Therapeutic Therapeutic or indications ＜Development country＞ exploratory confirmatory Filed Approved study study Articular cartilage In-house development dMD-001 lesion <Japan> Cavernous nerve In-house development dMD-
Slide 23: Topics
Topics FY2024 Q2 Financial Results Presentation 23
Slide 24: Biomaterials business
Biomaterials business Promoting and developing various projects in the biomaterials business based on alginate A high polymeric substance derived from brown algae Little impact on cells Possible to be processed into various forms and hardness FY2024 Q2 Financial Results Presentation 24
Slide 25: The cartilage repair material: dMD-001
The cartilage repair material: dMD-001 Composed of a sodium alginate solution with calcium chloride solution Usage image Implant dMD-001 into the cartilage-deficient area Sodium alginate solution Calcium chloride solution FY2024 Q2 Financial Results Presentation 25
Slide 26: A material that supports nerve regeneration: ReFeel
A material that supports nerve regeneration: ReFeel® A sheet material composed of sodium alginate and polyglycolic acid nonwoven fabric Product appearance of ReFeel® Usage image ReFeelⓇ Damaged nerves FY2024 Q2 Financial Results Presentation 26
Slide 27: FY2024 Q2 Financial Results Presentation
FY2024 Q2 Financial Results Presentation 27
Mochida Pharmaceutical — FY2024 Q2 Earnings Presentation on 6ix